Loading…
Loading…
ATXI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ATXI and 80,000+ other tickers.
See exactly how ATXI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ATXI and 80,000+ other tickers.
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Insider and Institutional Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe disease is a rare, inherited lysosomal storage disorder caused by deficiency of the enzyme acid α-glucosidase (GAA), resulting in progressive skeletal and respiratory muscle weakness.
Institutional and Insider Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over
Risk and Volatility Avenue Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Valuation and Earnings This table compares Avenue Therapeutics and ObsEva"s revenue, earnings
Profitability This table compares NexImmune and Avenue Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NexImmune N/A -534.32% -213.72% Avenue Therapeutics N/A -471.57% -296.50% Volatility and Risk NexImmune has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P